



April 26, 2021

**Initiatives Against COVID-19 in Canada**  
**- Health Canada Initiates the Review of the Rolling Submission**  
**for COVID-19 VLP Vaccine Candidate -**

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President & Representative Director; Hiroaki Ueno) announced today that its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; President; Takashi Nagao) announced on April 23 local time that Health Canada has initiated the review of the rolling submission for plant-derived virus-like particle (VLP) vaccine candidate in combination with GSK adjuvant (project code: MT-2766) from April 19 local time which has been developing by Medicago for the prevention of COVID-19.

Phase 3 part of its phase 2/3 clinical trials is currently ongoing in Canada and the US, and will take place in about 10 countries in Europe and Latin America, starting with the UK, Brazil.

Mitsubishi Tanabe Pharma Group will work to develop MT-2766 and deliver VLP vaccines to society as soon as possible, contributing even further to the prevention of COVID-19, a pressing social issue.

*Medicago release (April 23, 2021, local time)*

[Health Canada initiates the review of the rolling submission for the first Canadian-based COVID-19 vaccine candidate](#)

**Mitsubishi Tanabe Pharma Corporation**  
**Communication Crossroads Department**

Media contacts: TEL:+81 6 6205 5119